Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity

CONCLUSION: Alpelisib represents an active treatment option in patients with recurrent gynecological cancers harboring a PIK3CA mutation. These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers.PMID:38518529 | DOI:10.1016/j.ygyno.2024.02.029

Source: Gynecologic Oncology - March 22, 2024 Category: Cancer & Oncology Authors: Anna Passarelli Vittoria Carbone Sandro Pignata Roberta Mazzeo Domenica Lorusso Giovanni Scambia Stefania Canova Teresa Di Palma Giulia Tasca Mara Mantiero Emanuele Naglieri Claudia Andreetta Martina Rauso Anna Elisabetta Brunetti Letizia Laera Chiara Abe Source Type: research